Literature DB >> 23041457

Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma.

Sunil Saroha1, Robert G Uzzo, Elizabeth R Plimack, Karen Ruth, Tahseen Al-Saleem.   

Abstract

PURPOSE: A low absolute lymphocyte count is a likely index of poor systemic immunity that may be associated with aggressive features and inferior survival in patients with clear cell renal cell carcinoma.
MATERIALS AND METHODS: To determine the absolute lymphocyte count we retrospectively analyzed the preoperative blood count of 430 patients with a mean age of 60 years treated with primary surgical resection at our cancer center. Absolute lymphocyte count values as a continuous variable and at a level below 1,300 cells per μl, which was our lowest reference value, were correlated with nuclear grade, pathological stage and TNM stage. We used the Kaplan-Meier method to estimate overall survival, stratified by absolute lymphocyte count status.
RESULTS: As a continuous variable, low absolute lymphocyte count was associated with higher grade (p = 0.009), and higher pT stage (p = 0.034) and TNM stage (p <0.0001). Lymphopenia below 1,300 cells per μl was associated with high grade (p = 0.0043), pT stage (p = 0.051) and TNM stage (p <0.0001). At a median followup of 33.5 months lymphopenia was associated with inferior overall survival in a univariate model (p <0.0001), and on multivariate analysis independent of pT, N and M stages, patient age, grade, smoking history and comorbidities (p = 0.0102). Lymphopenia was also associated with inferior overall survival in a subset of young patients (age 60 years or less) with no distant metastasis (p = 0.014).
CONCLUSIONS: In 430 patients with clear cell renal cell carcinoma lymphopenia was associated with lower overall survival independent of pT and TNM stages, nuclear grade, age, tobacco smoking and comorbidity index.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23041457      PMCID: PMC3545104          DOI: 10.1016/j.juro.2012.09.166

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

1.  Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients.

Authors:  Tomas Gudbjartsson; Sverrir Hardarson; Vigdis Petursdottir; Asgeir Thoroddsen; Jonas Magnusson; Gudmundur V Einarsson
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

2.  Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.

Authors:  Scott E Eggener; Ofer Yossepowitch; Joseph A Pettus; Mark E Snyder; Robert J Motzer; Paul Russo
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

3.  Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.

Authors:  Revathi Suppiah; Philip E Shaheen; Paul Elson; Seema A Misbah; Laura Wood; Robert J Motzer; Slyvie Negrier; Steven W Andresen; Ronald M Bukowski
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

4.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

Authors:  Tarek M Mekhail; Rony M Abou-Jawde; Gabriel Boumerhi; Sareena Malhi; Laura Wood; Paul Elson; Ronald Bukowski
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

5.  Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.

Authors:  Igor Frank; Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

6.  Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy.

Authors:  Luca A Fumagalli; Jan Vinke; Wilco Hoff; Ellen Ypma; Ferdinando Brivio; Angelo Nespoli
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

7.  Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma.

Authors:  Vincenzo Ficarra; Guido Martignoni; Nicola Maffei; Matteo Brunelli; Giacomo Novara; Luisa Zanolla; Maurizio Pea; Walter Artibani
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

8.  The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma.

Authors:  H J Fahn; Y H Lee; M T Chen; J K Huang; K K Chen; L S Chang
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

9.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

10.  Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma.

Authors:  Cağatay Göğüş; Sümer Baltaci; Ercan Filiz; Atilla Elhan; Yaşar Bedük
Journal:  Urology       Date:  2004-03       Impact factor: 2.649

View more
  60 in total

1.  Scoring of prognostic parameters in patients with unresectable advanced or recurrent colorectal cancer undergoing chemotherapy.

Authors:  Masahide Ikeguchi; Ryugo Shimoda; Manabu Yamamoto; Yoshihiko Maeta; Keigo Ashida; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2013-09-11       Impact factor: 1.641

2.  Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma.

Authors:  Reza Mehrazin; Robert G Uzzo; Alexander Kutikov; Karen Ruth; Jeffrey J Tomaszewski; Essel Dulaimi; Serge Ginzburg; Philip H Abbosh; Timothy Ito; Anthony T Corcoran; David Y T Chen; Marc C Smaldone; Tahseen Al-Saleem
Journal:  Urol Oncol       Date:  2014-07-11       Impact factor: 3.498

3.  Score of the preoperative absolute number of lymphocytes, monocytes, and neutrophils as a prognostic indicator for patients with gastric cancer.

Authors:  Hiroaki Saito; Shota Shimizu; Yusuke Kono; Yuki Murakami; Yuji Shishido; Kozo Miyatani; Tomoyuki Matsunaga; Yoji Fukumoto; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-05-06       Impact factor: 2.549

4.  High postoperative neutrophil-to-lymphocyte ratio as a poor prognostic marker in patients with upper tract urothelial carcinoma.

Authors:  Kiyoaki Nishihara; Shigetaka Suekane; Kousuke Ueda; Makoto Nakiri; Mitsunori Matsuo; Tsukasa Igawa
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

5.  Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer.

Authors:  Hiroaki Saito; Yusuke Kono; Yuki Murakami; Yuji Shishido; Hirohiko Kuroda; Tomoyuki Matsunaga; Yoji Fukumoto; Tomohiro Osaki; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

6.  The impact of the preoperative peripheral lymphocyte count and lymphocyte percentage in patients with colorectal cancer.

Authors:  Yasuhito Iseki; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsuro Tamura; Go Ohira; Sadaaki Yamazoe; Kenjiro Kimura; Takahiro Toyokawa; Ryosuke Amano; Hiroaki Tanaka; Kazuya Muguruma; Kosei Hirakawa; Masaichi Ohira
Journal:  Surg Today       Date:  2016-10-25       Impact factor: 2.549

7.  Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.

Authors:  Minoru Kobayashi; Taro Kubo; Kenji Komatsu; Akira Fujisaki; Fumihito Terauchi; Shinsuke Natsui; Akinori Nukui; Shinsuke Kurokawa; Tatsuo Morita
Journal:  Med Oncol       Date:  2013-03-29       Impact factor: 3.064

8.  A clinical investigation of the association between perioperative oral management and prognostic nutritional index in patients with digestive and urinary cancers.

Authors:  H Otagiri; S Yamadav; M Hashidume; A Sakurai; M Morioka; E Kondo; H Sakai; H Kurita
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

9.  Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer.

Authors:  Juanjuan He; Pengwei Lv; Xue Yang; Yanli Chen; Chao Liu; Xinguang Qiu
Journal:  Tumour Biol       Date:  2016-01-13

10.  Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma.

Authors:  Yuan Chang; Qiang Fu; Le Xu; Lin Zhou; Zheng Liu; Yuanfeng Yang; Zongming Lin; Jiejie Xu
Journal:  Tumour Biol       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.